Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
A New Jersey retirement tax quirk can erase part of a $1.8 million nest egg, costing about $11,400 annually. crib not...
Banking, housing finance groups urge federal regulators to tailor Basel III capital rules, arguing that overlap and h...
A former social security commissioner argues for higher taxes on the wealthy to shore up Social Security. The idea so...
A new study finds that companies investing heavily in AI per employee are expanding payrolls faster, with notable gai...
A small nuclear energy company under $4B could ride a global revival in clean power. Learn how to evaluate this nucle...
A yearly reshuffle of Medicare Part D pharmacy networks can swing out-of-pocket costs for maintenance meds. Investors...
Visa extends its four-year partnership with Red Bull Racing, expanding branding and fan experiences amid lingering qu...
DATs openly hold crypto on their balance sheets, letting investors gain exposure by buying stock. This piece explains...
A nationwide look at housing inventory startling trends reveals sharp market divergence. Texas pockets show rising li...
A leading fiscal watchdog warns that the U.S. is entering a high-risk moment as debt nears 100% of GDP and calls for ...
Oil has moved markets again, with crude flirting with triple digits and energy stocks lighting up in response. This g...